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We studied 1,432 febrile travelers from Sweden who 
had returned from malaria-endemic areas during March 
2005–March 2008. In 383 patients, paired serum samples 
were blindly analyzed for inﬂ  uenza and 7 other agents. For 
21% of 115 patients with fever of unknown origin, serologic 
analysis showed that inﬂ  uenza was the major cause. 
M
any travelers who return from tropical countries 
have fever of unknown etiology (1–11). Earlier stud-
ies focusing on fever in returning travelers have used an 
observation study design with no standardized diagnostics 
(1–11). With the exception of studies generated from the 
GeoSentinel database (2,8), all are single-center studies. In 
Sweden, guidelines from the National Board of Health and 
Welfare advise febrile travelers returning from malaria-
endemic areas to be examined at departments of infectious 
diseases. The objective of this multicenter study was to in-
vestigate causes of unknown fever by uniformly analyzing 
paired serum samples.
The Study
The study took place in Sweden from March 14, 2005 
through March 14, 2008 at 5 hospitals that had infectious 
diseases departments. Inclusion criteria were travel within 
the past 2 months to a malaria-endemic area as deﬁ  ned by 
the World Health Organization, age >18 years, documented 
temperature >38°C at admission or within the previous 2 
days, and a decision by the examining clinician to obtain a 
blood ﬁ  lm for suspected malaria.
Participants were identiﬁ  ed either through prospective 
case ﬁ  nding at emergency rooms and outpatient clinics or 
through retrospective case ﬁ  nding of eligible patients who 
had not been included in the prospective case ﬁ  nding; these 
patients were identiﬁ  ed through listings of all performed 
malaria diagnostics. All included patients had been sub-
ject to diagnostic investigations (e.g., cultures, serologic 
analysis, radiographs) on the basis of clinical symptoms 
and signs as part of routine procedures at each hospital. An 
infectious diseases specialist at each study site conﬁ  rmed 
the diagnosis based on results of investigations performed. 
The following variables were recorded for all patients: age, 
gender, travel history (destination, duration, and purpose), 
diagnosis, and if applicable, days of hospitalization.
Information about pretravel immunizations and time 
between return to Sweden and onset of symptoms was 
available only in the group of prospectively included pa-
tients. Travel destinations were grouped as Africa, Asia, 
and America. Purpose of travel was divided into 3 catego-
ries: tourism, Swedish residents originating from a malaria-
endemic country and visiting friends and relatives in their 
country of origin, or other.
Paired serum samples from prospectively included pa-
tients were blindly analyzed for antibodies to inﬂ  uenza A 
and B viruses, dengue virus, chikungunya virus, Brucella 
spp.,  Leptospira spp., Coxiella burnetii,  Rickettsia  spp., 
spotted fever group (SFG) rickettsia, and typhus, respec-
tively. If the travel destination was Asia, Orientia tsutsuga-
mushi and Japanese encephalitis virus were also analyzed 
(Figure). A >4-fold rise in reciprocal antibody titer against 
a relevant pathogen was considered a positive result. Com-
parisons between 2 groups were made by using univariate 
statistics (χ2 test); a p value <0.05 was considered signiﬁ  -
cant. The study was approved by the regional Ethics Com-
mittee at Karolinska Institute, Stockholm.
In 1,432 febrile travelers, the inclusion criteria were 
fulﬁ  lled. A total of 514 patients were identiﬁ  ed through 
prospective case-ﬁ  nding, and 383 of those agreed to be fur-
ther tested by using blinded serologic analysis; 918 patients 
were retrospectively identiﬁ   ed. Characteristics of these 
groups are shown in Table 1. Among the entire group (n = 
1,432) before results of additional blinded serologic analy-
sis were obtained, unknown fever was diagnosed in 34%, 
febrile gastroenteritis in 24%, malaria in 6%, inﬂ  uenza in 
3%, and dengue fever in 2.5%. In the 383 prospectively 
included patients, the diagnosis was unknown fever in 115 
(30%); additional serologic analysis established a diagno-
sis in 24 (21%) of these patients.
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1These authors contributed equally to this article.The most common diagnosis was inﬂ  uenza (n = 12) 
followed by SFG rickettsial infection (n = 5), dengue fever 
(n = 3), leptospirosis (n = 2), Q fever (n = 1), and rickettsial 
infection caused by O. tsutsugamushi (n = 1). A positive 
serologic result added a co-infection to 23 patients with a 
diagnosis of illness other than unknown fever; these co-
infections were inﬂ  uenza (n = 14), dengue fever (n = 3), 
typhus group rickettsial infections (n = 2), SFG rickettsial 
infection (n = 2), leptospirosis (n = 1), and chikungunya fe-
ver (n = 1). All infections diagnosed by additional blinded 
serologic analysis were mild and self-limiting, and the main 
symptom was fever without typical clinical signs. Fever of 
unknown etiology was diagnosed in 24% and inﬂ  uenza in 
9% of the patients with additional serologic analysis, com-
pared with 35% and 4%, respectively, in the group with 
routine investigations only (Table 2).
Thirty-six patients in the prospectively included group 
(n = 514) had inﬂ  uenza diagnosed by both routine exami-
nation and additional serologic analysis. Eighteen of the 36 
became ill with fever either just before returning to Sweden 
or within 1 day of arrival, indicating that they acquired the 
infection abroad; 5 had been home 1–2 days, indicating that 
the infection could have been acquired either during travel 
or after the return; and 13 patients had returned from travel 
>3 days before falling ill with fever, indicating that they 
most likely became infected in Sweden. Twenty-ﬁ  ve of the 
36 inﬂ  uenza patients had veriﬁ  ed inﬂ  uenza A infection, and 
11 had inﬂ  uenza B infection. Nine (25%) patients became 
ill after returning from a trip occurring well outside the in-
ﬂ  uenza season of the northern hemisphere; 7 had visited 
Africa, and 2 had traveled to Asia.
Conclusions
Inﬂ  uenza is often missed in routine diagnostics of fe-
brile travelers. Our ﬁ  ndings highlight the role of travel in 
the global spread of inﬂ  uenza and corroborate the ﬁ  ndings 
of inﬂ  uenza in travelers by others (12,13). Apart from in-
ﬂ  uenza, the most common diseases missed in routine in-
vestigations were rickettsial infections, dengue fever, and 
leptospirosis. Our study adds a new approach by using a 
systematic collection of paired sera. The retrospective case 
ﬁ  nding is not fully comparable with the prospective inclu-
sion of patients, and we are missing some retrospective 
data on type and length of travel. These missing data are, to 
some extent, compensated by a careful retrospective review 
of all 918 patients’ ﬁ  les, the ﬁ  nding that the characteristics 
of the 2 groups are similar, and the similarity of the routine 
investigations for both groups.
DISPATCHES
1806  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 15, No. 11, November 2009
Paired serum
samples
N = 383
Leptospirosis
ELISA IgM
Chikungunya
IF IgG
Q fever
ELISA
IgM+IgG
Dengue
IF IgG
Rickettsia spp
Typhus group
Spotted fever group
micro-IF
Influenza A+B
ELISA IgG
Brucellosis
ELISA 
IgG+IgM
ELISA IgM
MAT
PCR
Orientia
tsutsu-
gamushi
IF IgG
Japanese
encephalitis
IF IgM+IgG
+
- +
Only if
travel
destination 
was Asia
Micro-IF
+
Figure. Flow chart of serologic methods performed blindly on all 
paired serum samples (n = 383), Sweden. Ig, immunoglobulin; 
MAT, microscopic agglutination test; IF, immunoﬂ  uorescent.
Table 1. Characteristics of 1,432 febrile travelers returning from tropical countries, Sweden, March 2005–March 2008* 
Patients with routine investigations 
Characteristics
Prospectively 
identified, n = 131 
Retrospectively 
identified, n = 918 
Prospectively identified patients with 
routine investigation + additional 
serologic analysis, n = 383 
Median age, y (range)  32 (18–65)  36 (18–84)  37 (18–76) 
Median duration of stay, d  20 21† 20
Female gender  56 (43)  420 (46)  162 (42) 
Travel to Africa  69 (53)  430 (47)  199 (52) 
Travel to Asia  53 (40)  427 (46)  169 (44) 
Travel to America  10 (8)  63 (7)  20 (5) 
Tourists 76 (58)  581(63)‡  247 (64) 
VFR 10 (8), p = 0.05§  126 (14)‡  20 (5), p<0.0001§ 
Pretravel influenza immunization  8 (6)  NA 53 (14) 
Hospitalized after return to Sweden  37 (28)  258 (28)  123 (32) 
*Values are no. (%) patients except as indicated. Some travelers visited >1 region, making the percent sum >100%. VFR, visiting friends and relatives 
(Swedish residents who were born in a malaria-endemic country and who had visited friends and relatives in their country of origin); NA, not applicable. 
†In 115 patient files, this information was missing. 
‡In 39 patient files, information on type of travel was missing. 
§Compared with retrospectively identified patients. Fever in Returned Travelers, Sweden
Additional blinded serologic analyses were performed 
by using the same method in the same laboratories. The pro-
portion of ﬁ  nal diagnoses with fever of unknown etiology 
was high compared with that of other studies, even after re-
sults of the additional serologic analysis (1–8,11). This large 
proportion of fever with unknown etiology may be explained 
by the unselected study population in a hospital setting and 
by a high patient turnover; febrile travelers with a negative 
malaria ﬁ  lm and in good clinical condition are often sent 
home without extensive investigations or follow up.
To estimate the number of nasopharyngeal swabs tak-
en as a routine test, we retrospectively reviewed a sample 
of 217 patient ﬁ  les and found that 31 (14%) had been tested 
for inﬂ  uenza; 6 of those tests yielded positive results. Age, 
gender ratio, destinations, duration of travel, and hospital-
ization rates were similar to those of recent studies (3,7,8). 
The ﬁ  nding of undiagnosed rickettsial infections shows that 
symptoms are often nonspeciﬁ  c, and serologic response of-
ten delayed (14).
Our results indicate that leptospirosis is an underesti-
mated cause of fever in returned travelers and is not only 
related to extreme sports (15). The relatively low frequency 
of additional rickettsial infections, dengue, and leptospiro-
sis indicates that paired sera should not be routinely recom-
mended without a speciﬁ  c clinical suspicion. However, this 
study supports the theory that diseases with classic clinical 
ﬁ  ndings according to text books can also manifest as fever 
only. Inﬂ  uenza should always, in all seasons, be considered 
when diagnosing illness in returning febrile travelers.  
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